Effects of Platelet-rich Plasma on Ocular Surface in Patients with Dry Eye Syndrome: Clinico-experimental Analysis

Purpose To verify the presence of dry eye syndrome (DES) in treated patients with glaucoma and to analyze DES's impact on the patients' quality of life (QOL) versus the control group. Methods In this observational cross-sectional study, 61 patients were enrolled at a clinical practice. Patients were divided into three groups by number of glaucoma drops instilled per day (G1=1 drop/day, G2=2 drops/day, G3=3 drops/day). A control group of 20 subjects was also selected (G0). All subjects were submitted to a complete ocular examination (including tear function and ocular surface status) and completed the 25-item National Eye Institute Visual Function Questionnaire (NEI-VFQ), Glaucoma Symptom Scale (GSS) questionnaire, and Ocular Surface Disease Index (OSDI). DES was defined as presence of punctate keratitis and decreased break-up time. Statistical analysis was performed applying the Kruskal-Wallis analysis of variance and Mann-Whitney U tests (to compare median values between groups) as well as the χ2 and Fisher test (to verify significant differences). Results A total of 40% of G3 and 39% of G2 patients presented DES versus 11% of G1 and 5% of G0 (p=0.01). QOL was significantly influenced and altered (NEI-VFQ 25 total mean and GSS total mean and symptoms average: p=0.0085, p=0.006, and p=0.03, respectively). OSDI pointed out differences by group: 26% of G2 and 15% of G3 presented moderate OSDI and 15% of G3 and 8.7% of G2 severe OSDI (p>0.05). Conclusions Patients with topically treated glaucoma present DES more often than a similar control group (p=0.01). The presence of DES negatively influences the patient's QOL. The patients with glaucoma's ocular surface status should be evaluated regularly to ensure the timely detection and treatment of pathologic signs on the ocular surface.

Download Full-text

Comparison of treatment efficacy between 100% platelet-rich plasma and 100% serum eye drops in moderate-to-severe dry eye disease: a randomised controlled trial protocol

BMJ Open ◽

10.1136/bmjopen-2020-048479 ◽

2021 ◽

Vol 11 (6) ◽

pp. e048479

Author(s):

Passara Jongkhajornpong ◽

Pawin Numthavaj ◽

Thunyarat Anothaisintawee ◽

Kaevalin Lekhanont ◽

Gareth McKay ◽

...

Keyword(s):

Dry Eye ◽

Ocular Surface ◽

Platelet Rich Plasma ◽

Controlled Trial ◽

Dry Eye Disease ◽

Autologous Serum ◽

Eye Disease ◽

Eye Drops ◽

Department Of Ophthalmology ◽

Autologous Platelet

IntroductionDry eye disease (DED) is a common eye problem. Although the disease is not fatal, it substantially reduces quality of life and creates a high economic burden, especially in patients with moderate-to-severe DED. Several biological tear substitutes (eg, autologous serum (AS), autologous platelet-rich plasma (APRP) and autologous platelet lysate) could effectively improve dry eyes. However, evidence on their comparative efficacy is controversial. This study aims to compare the efficacy of 100% APRP with 100% AS eye drops in patients with moderate-to-severe DED.Methods and analysisThe study is a single-centre, double-blinded randomised, parallel, non-inferiority trial. One hundred and thirty patients with moderate-to-severe DED, aged 18–70 years will be recruited from outpatient clinic, Department of Ophthalmology, Ramathibodi Hospital, Bangkok from February 2021 to January 2023. Patients will be randomised to receive either 100% APRP or 100% AS eye drops (1:1 ratio) for 4 weeks. The primary outcomes are ocular surface disease index (OSDI) and ocular surface staining (OSS) evaluated using the Oxford scale. Secondary outcomes are fluorescein break-up time, Schirmer’s I test, meibomian gland parameters and adverse events. Other measured outcomes include best-corrected visual acuity, intraocular pressure and compliance.Ethics and disseminationThe study protocol and any supplements used in conducting this trial have been approved by the Ethics Committee of Faculty of Medicine, Ramathibodi Hospital, Mahidol University (MURA2020/1930). Informed consent will be obtained from all patients before study entry. Results will be presented in peer-reviewed journals and international conferences.Trial registration numberNCT04683796.

Download Full-text

Changes the Ocular Surface after Corneal Refractive Surgery. Review

Ophthalmology in Russia ◽

10.18008/1816-5095-2020-3-344-350 ◽

2020 ◽

Vol 17 (3) ◽

pp. 344-350

Author(s):

S. V. Trufanov ◽

E. V. Sukhanova ◽

A. A. Tyurina

Keyword(s):

Dry Eye ◽

Ocular Surface ◽

Refractive Surgery ◽

High Efficiency ◽

High Specificity ◽

Functional Results ◽

Dry Eye Syndrome ◽

Specificity And Sensitivity ◽

Surgery Research ◽

Corneal Refractive Surgery

Modern corneal refractive surgery provides high efficiency, safety, predictability and stability of the different ametropia kinds correction’s clinically-functional results. However, in overwhelming percentage of cases, having spent some time after surgery patients complain about discomfort, eyes dryness, burning, feel gritty, redness, blurred and vision instability. Complaints mentioned above are caused by the appearance of transitory dry eye syndrome. Main etiology and pathogenesis factors of this disease are presented in this review. The results of dry eye syndrome classical diagnosis methods have been analyzed, as well as modern techniques, characterized by high specificity and sensitivity, which allow to increase the dry eye’s diagnostics accuracy. The study of the dry syndrome after corneal refractive surgery is devoted to a huge number of works of domestic and foreign authors. However, at present time there is no unique algorithm for assessing the damage of the ocular surface before and after corneal refractive surgery, which would include a set of high-precision and specific techniques for quickly and reliably evaluate the severity of dry eye syndrome, allowing to develop preventive measures and pathogenetically oriented treatment and, thereby, accelerate rehabilitation of patients after surgery. Research continuation is needed in this direction.

Download Full-text

Micro-instillation of fluorescein with an inoculation loop for ocular surface staining in dry eye syndrome

Acta Ophthalmologica ◽

10.1111/aos.13559 ◽

2017 ◽

Vol 96 (2) ◽

pp. e140-e146 ◽

Cited By ~ 1

Author(s):

Emilie Courrier ◽

Didier Renault ◽

Mathilde Kaspi ◽

Agathe Marcon ◽

Victor Lambert ◽

...

Keyword(s):

Dry Eye ◽

Ocular Surface ◽

Dry Eye Syndrome ◽

Surface Staining

Download Full-text

Ocular surface epithelial thickness evaluation with spectral‐domain optical coherence tomography in patients with dry eye syndrome

Acta Ophthalmologica ◽

10.1111/j.1755-3768.2011.417.x ◽

2011 ◽

Vol 89 (s248) ◽

pp. 0-0

Author(s):

M FRANCOZ ◽

I KARAMOKO ◽

C BAUDOUIN ◽

A LABBE

Keyword(s):

Optical Coherence Tomography ◽

Dry Eye ◽

Ocular Surface ◽

Dry Eye Syndrome ◽

Spectral Domain ◽

Optical Coherence ◽

Epithelial Thickness ◽

Thickness Evaluation

Download Full-text

In Vivo Anti-Inflammation Potential of Aster koraiensis Extract for Dry Eye Syndrome by the Protection of Ocular Surface

Nutrients ◽

10.3390/nu12113245 ◽

2020 ◽

Vol 12 (11) ◽

pp. 3245

Author(s):

Sung-Chul Hong ◽

Jung-Heun Ha ◽

Jennifer K. Lee ◽

Sang Hoon Jung ◽

Jin-Chul Kim

Keyword(s):

Animal Model ◽

Er Stress ◽

Dry Eye ◽

Lacrimal Gland ◽

Ocular Surface ◽

Inflammatory Responses ◽

Dry Eye Syndrome ◽

Inhibitory Effects ◽

Food Material

Dry eye syndrome (DES) is a corneal disease often characterized by an irritating, itching feeling in the eyes and light sensitivity. Inflammation and endoplasmic reticulum (ER) stress may play a crucial role in the pathogenesis of DES, although the underlying mechanism remains elusive. Aster koraiensis has been used traditionally as an edible herb in Korea. It has been reported to have wound-healing and inhibitory effects against insulin resistance and inflammation. Here, we examined the inhibitory effects of inflammation and ER stress by A. koraiensis extract (AKE) in animal model and human retinal pigmented epithelial (ARPE-19) cells. Oral administration of AKE mitigated DE symptoms, including reduced corneal epithelial thickness, increased the gap between lacrimal gland tissues in experimental animals and decreased tear production. It also inhibited inflammatory responses in the corneal epithelium and lacrimal gland. Consequently, the activation of NF-κB was attenuated by the suppression of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). Moreover, AKE treatment ameliorated TNF-α-inducible ocular inflammation and thapsigargin (Tg)-inducible ER stress in animal model and human retinal pigmented epithelial (ARPE-19) cells. These results prove that AKE prevents detrimental functional and histological remodeling on the ocular surface and in the lacrimal gland through inhibition of inflammation and ER stress, suggesting its potential as functional food material for improvement of DES.

Download Full-text